10-QPeriod: Q1 FY2008

ABBOTT LABORATORIES Quarterly Report for Q1 Ended Mar 31, 2008

Filed May 2, 2008For Securities:ABT

Summary

Abbott Laboratories reported strong financial results for the first quarter ended March 31, 2008, demonstrating robust growth across its key business segments. Net sales increased by 13.8% to $6.77 billion, driven by significant contributions from Pharmaceutical Products and Diagnostic Products. Net earnings rose to $937.9 million, or $0.60 per diluted share, a notable improvement from the prior year. The company also continued its commitment to returning value to shareholders, increasing cash dividends and actively repurchasing shares. The company's performance was bolstered by the weakening U.S. dollar, which positively impacted international sales. Key products like HUMIRA and Depakote showed strong sales growth, contributing significantly to the Pharmaceutical Products segment's performance. While facing generic competition in some areas, such as Omnicef, Abbott's diversified portfolio and strategic investments in research and development position it well for continued growth.

Financial Highlights

5 data points
Beta

Revenue

$6.77B

56.2% Gross Margin

Net Income

$937.90M

13.9% Net Margin

EPS (Diluted)

$0.60

Financial Statements
Beta
Revenue$6.77B
Gross Profit$3.80B
Net Income$937.90M
EPS (Basic)$0.61
EPS (Diluted)$0.60

Key Highlights

  • 1Net sales increased by 13.8% to $6.77 billion for the first quarter of 2008 compared to the same period in 2007.
  • 2Net earnings rose to $937.9 million ($0.60 per diluted share) in Q1 2008, up from $697.5 million ($0.45 per diluted share) in Q1 2007.
  • 3Pharmaceutical Products segment sales grew by 14.3% to $3.85 billion, driven by strong performance of HUMIRA and Depakote.
  • 4The company declared a cash dividend of $0.36 per share, an increase from $0.325 per share in the prior year.
  • 5Abbott repurchased approximately 15.6 million shares of common stock during the first quarter of 2008 for approximately $800 million.
  • 6A significant subsequent event is the conclusion of the TAP Pharmaceutical Products Inc. joint venture with Takeda on April 30, 2008, with Abbott gaining full control of the Lupron business.
  • 7The weakening U.S. dollar had a positive impact, increasing consolidated net sales by 5.5% in the first quarter of 2008.

Frequently Asked Questions

Sales growth was driven by strong performance across multiple segments, particularly Pharmaceutical Products and Diagnostic Products. The weakening U.S. dollar also significantly boosted international sales. Key products like HUMIRA and Depakote showed substantial sales increases, contributing to the overall growth.

Abbott and Takeda concluded their TAP joint venture on April 30, 2008. Abbott gained full control of the Lupron business, which is expected to be neutral to slightly accretive to earnings. While the immediate financial impact is being assessed, the long-term strategic benefit of consolidating this business is a key consideration for investors.

Abbott continues to prioritize returning capital to shareholders. The company increased its cash dividend and actively repurchased approximately $800 million of its common shares in the first quarter of 2008, demonstrating confidence in its financial health and commitment to shareholder value.

Abbott is involved in various legal proceedings, including patent disputes and pricing-related litigation. While management believes most of these will not have a material adverse effect, some could be material to quarterly financial results. The company has recorded reserves for estimated losses where probable and measurable, but also notes uncertainties in predicting outcomes for several significant cases.